Drug Trial Radar · NCT02814916
Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA
Last checked: Nov 19, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
199
Actual
Start
Mar 30, 2017
Primary completion
Jan 1, 2024
Study completion Jan 1, 2024
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Jun 28, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 0 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To determine the safety and descriptive efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections in children, aged birth to 17 years (inclusive), known or suspected to be caused by susceptible Gram-positive organisms, including methicillin-resistant strains of Staphylococcus aureus.
Conditions
- Methicillin-Resistant Staphylococcus Aureus
- Bacterial Infections
- Staphylococcal Skin Infections
Interventions
DalbavancinDrug
Dalbavancin was administered intravenously over 30 (± 5) minutes.
VancomycinDrug
Vancomycin was administered intravenously over 60 (± 10) minutes every 6 (± 1) hours.
OxacillinDrug
Oxacillin was administered intravenously over 60 (± 10) minutes every 6 (± 1) hours.
FlucloxacillinDrug
Flucloxacillin was administered intravenously over 60 (± 10) minutes every 6 (± 1) hours.
CefadroxilDrug
Cefadroxil was administered orally every 12 hours.
ClindamycinDrug
Clindamycin was administered orally every 8 hours.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Shift From Baseline in Distortion Product Otoacoustic Emission at TOC VisitTime frame: Baseline, Day 28 (± 2 days)
- Shift From Baseline in Auditory Brainstem Response Test at TOC VisitTime frame: Baseline, Day 28 (± 2 days)
- Shift From Baseline in Acoustic Immittance Test at TOC VisitTime frame: Baseline, Day 28 (± 2 days)
- Shift From Baseline in Behavioral Audiometric Valuation at TOC VisitTime frame: Baseline, Day 28 (± 2 days)
- Shift From Baseline in Clostridium Difficile (CD) and Vancomycin-resistant Enterococci (VRE) at TOC VisitTime frame: Baseline, Day 28 (± 2 days)
Locations
84 sites in 20 countries. Site status is shown where the registry gives one.
University of South Alabama /ID# 237446
Mobile, Alabama
Valleywise Health Medical Center /ID# 234343
Phoenix, Arizona
Southbay Pharma Research /ID# 235700
La Palma, California
University of California, Los Angeles /ID# 237533
Los Angeles, California
Duplicate_Children's Hospital Colorado /ID# 237622
Aurora, Colorado
Global Research Holdings LLC /ID# 235747
Panama City, Florida
Tampa General Hospital /ID# 237061
Tampa, Florida
Children's Healthcare of Atlanta - Ferry Rd /ID# 237003
Atlanta, Georgia
University of Maryland Medical Center /ID# 234353
Baltimore, Maryland
Duplicate_Children's Mercy Hospital and Clinics /ID# 237800
Kansas City, Missouri
Robert Wood Johnson Univ Hosp /ID# 237862
New Brunswick, New Jersey
NYU School of Medicine /ID# 236783
New York, New York
SUNY Upstate Medical University /ID# 236831
Syracuse, New York
Duke University Medical Center /ID# 234315
Durham, North Carolina
Cleveland Clinic Main Campus /ID# 237564
Cleveland, Ohio
Hospital de Ninos Dr. Orlando Alassia /ID# 235562
Santa Fe, Argentina
Grodno Regional Infectious Disease Hospital /ID# 235661
Grodno, Belarus
Mogilev Regional Children's Hospital /ID# 235657
Mogilev, Belarus
Vitebsk Regional Clinical Center for Children /ID# 235659
Vitebsk, Belarus
Duplicate_Hospital Pequeno Princípe /ID# 235629
Curitiba, Paraná, Brazil
Duplicate_Irmandade Santa Casa de Misericórdia de Porto Alegre /ID# 235627
Porto Alegre, Rio Grande do Sul, Brazil
University Multiprofile Hospital for Active Treatment Deva Maria EOOD Burgas /ID# 235965
Bulgas, Bulgaria
MHAT (Multiprofile Hospital for Active Treatment) /ID# 235539
Kozloduy, Bulgaria
UMHAT Dr Georgi Stranski EAD /ID# 237829
Pleven, Bulgaria
UMHAT Dr Georgi Stranski EAD /ID# 237830
Pleven, Bulgaria
Multiprofile Hospital for Active Treatment ( UMHAT) Sveti Georgi EAD Plovdiv /ID# 235487
Plovdiv, Bulgaria
UMHAT Sveti Georgi /ID# 237026
Plovdiv, Bulgaria
UMHAT Kanev /ID# 237809
Rousse, Bulgaria
Medical center 1 Sevlievo /ID# 237470
Sevlievo, Bulgaria
MHATEM N.I.Pirogov Septic Surgery Clinic /ID# 235541
Sofia, Bulgaria
SHAT Hematologic Diseases /ID# 237915
Sofia, Bulgaria
University Multiprofile Hospital for Active Treatment Prof. Dr. Stoyan Kirkovich /ID# 235543
Stara Zagora, Bulgaria
Hospital de Ninos Dr. Roberto del Rio /ID# 235568
Independencia, Chile
Hospital El Carmen de Maipú /ID# 235570
Santiago, Chile
Hospital Universitario San Vic /ID# 238117
Medellín, Colombia
Fundacion Cardioinfantil /Id# 238041
Bogota, Cundinamarca, Colombia
Unidad De Investigacion Clinica Universidad De La Sabana /ID# 235566
Chía, Cundinamarca, Colombia
LTD Unimedi Kakheti Batumi Maternal and Child Healthcare Center /ID# 235643
Batumi, Georgia
LEPL Tbilisi State Medical University Givi Zhvania Academic Clinic of Pediatry /ID# 235645
Tbilisi, Georgia
LTD M. Iashvili Children's Central Hospital /ID# 235639
Tbilisi, Georgia
Showing 40 of 84 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.